Janux Therapeutics Inc (JANX) Company Profile & Statistics

Janux Therapeutics Inc
JANX
(Nasdaq - US)
N/A
46.38
-1.61 (-3.35%)
in:usd•As of: May 21, 2024 11:33 UTC -4
Open
46.84
High
48.36
Low
46.14

About Janux Therapeutics Inc

CEO

David Campbell

Headquarters

10955 vista sorrento parkway, suite 200

san diego, ca 92130, united states

Auditor

Ernst & Young LLP

Employees

Share Holders

Website

www.januxrx.com

Industry

biotechnology

Sector

health technology

Company Overview

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

Janux Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	2.40B
Enterprise Value	2.19B
Enterprise Value/EBITDA (ttm)	-27.88
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	3.72
Price to Sales (ttm)	335.14
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-762.92%
Profit Margin (ttm)	-943.17%
Return on Equity (ttm)	-13.49%
Return on Invested Capital (ttm)	-14.83%
Return on Assets (ttm)	-12.37%

Income Statement

Revenue (ttm)	7.29M
Revenue Per Share (ttm)	0.14
Gross Profit (ttm)	7.29M
EBITDA (ttm)³	-78.62M
Net Income Avi to Common (ttm)	-55.59M
Diluted EPS (ttm)	-1.22

Share Statistics

Beta (5Y Monthly)	3.87
52-Week Change	242.79%
S&P500 52-Week Change	26.74%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	51.85M
Dividend Yield	0.00%
Float ⁴	33.50M
% Held by Insiders	35.40%
% Held by Institutions	75.39%

Balance Sheet

Total Cash (mrq)	651.76M
Total Cash Per Share (mrq)	12.57
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	62.09%
Quick Ratio (mrq)	62.09%
Book Value Per Share (mrq)	12.65

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.30
Free Cash Flow (ytd)	-15.03M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Janux Therapeutics Inc

Trade With A Regulated Broker